Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Topotecan is an antineoplastic agent used to treat ovarian cancer, small cell lung cancer, or cervical cancer. It works by inhibiting DNA topoisomerases, type I.
- Mechanism
- Curator reviewed
Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death).
Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor.
- Primary indication
- For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens.Curator reviewed · 9 structured indications
- Formula / weight
- C23H23N3O5 · 421.4458 g/mol (avg)
- First approval
- Canada, 2009 · United States, 1996 · European Union, 2016
- Also known as
- hycamptamine
- Code names
- SK&F-104864 · SKF S-104864-A
- Brand names
- Hycamtin
Resolves to
UCFGDBYHRUNTLO-QHCPKHFHSA-NSMILESCC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Topotecan, and which of those have an active Phase 3 trial?